RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.
13 Sep, 2022 | 13:03h | UTCFive-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence